Form 4: OnKure Therapeutics CEO Nicholas Saccomano Granted Stock Options
SEC Form 4 Filing
OnKure Therapeutics CEO Nicholas Saccomano was granted 130,000 stock options on January 27, 2025, which vest monthly over four years.
Summary
- On January 27, 2025, Nicholas Saccomano, the President and CEO of OnKure Therapeutics, was granted 130,000 employee stock options.
- The exercise price of these options is $5.19 per share.
- The options vest monthly, with 1/48th of the shares vesting each month starting February 27, 2025, provided Saccomano remains a service provider.
- The options expire on January 26, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The grant of stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the options is dependent on the future performance of the company's stock price.
- If the CEO leaves the company before the options fully vest, they may forfeit some or all of the options.
Future Outlook
The vesting of the stock options is contingent on the CEO's continued service with the company.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for incentivizing executives in the biotech industry.
- The vesting schedule of 1/48th per month is a typical vesting structure for executive stock options.
- The exercise price of $5.19 is specific to OnKure's stock and market conditions at the time of the grant.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/27/2025 | Date of the stock option grant to Nicholas Saccomano. |
| 02/27/2025 | Start date for monthly vesting of the stock options. |
| 01/26/2035 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, OnKure Therapeutics, Nicholas Saccomano, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.